SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
NEW APPROACHES TO OPTIMIZE DRUG DOSING: LONG ACTING AND BEYOND
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
8 of
8
|
CABOTEGRAVIR PPK SIMULATION TO INFORM Q2M STRATEGIES FOLLOWING DOSING INTERRUPTIONS (ABSTRACT
373)
Susan L Ford
GlaxoSmithKline, Research Triangle Park, NC, USA
IN SILICO PREDICTION OF LONG-ACTING CABOTEGRAVIR PK IN LIVER-IMPAIRED PATIENTS (ABSTRACT
374)
Nicolas Cottura
University of Liverpool, Liverpool, United Kingdom
PHARMACOKINETICS OF LENACAPAVIR, AN HIV-1 CAPSID INHIBITOR, IN HEPATIC IMPAIRMENT (ABSTRACT
375)
Vamshi Jogiraju
Gilead Sciences, Inc, Fremont, CA, USA
MODEL-INFORMED DOSE SELECTION FOR ISLATRAVIR/MK-8507 ORAL ONCE-WEEKLY PHASE 2B STUDY (ABSTRACT
376)
Bhargava Kandala
Merck & Co, Inc, Bridgewater, NJ, USA
IN SILICO PREDICTION OF MONTHLY BICTEGRAVIR MICRONEEDLE ARRAY PATCHES (ABSTRACT
377)
Hannah Kinvig
University of Liverpool, Liverpool, United Kingdom
PBPK MODELING OF DEXAMETHASONE IN PATIENTS WITH COVID-19 AND LIVER DYSFUNCTION (ABSTRACT
378)
Maiara Camotti Montanha
University of Liverpool, Liverpool, United Kingdom
IN VIVO EVALUATION OF LONG-ACTING BIODEGRADABLE EMTRICITABINE IMPLANTS (ABSTRACT
379)
Megan Neary
University of Liverpool, Liverpool, United Kingdom
PHARMACOGENOMIC TESTING PROVIDES INSIGHT AND ENHANCES MEDICATION MANAGEMENT IN PLWHIV (ABSTRACT
380)
John D Zeuli
Mayo Clinic, Rochester, MN, USA
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
8 of
8
|
